Page 154 - Eceptor News Today

In a new review study, researchers aimed to describe the emergence of the Omicron variant, its structure, its impact on health and health systems, and the challenges that can be expected due to this variant.

A study posted suggested the inhibition of TBK1 and its homolog KKε could decrease the severity of COVID-19.

According to the Global Burden of Disease study, neurological disorders are the leading cause of disability and the second leading cause of death after heart disease.

Collaboration leverages BioNTech's multi-platform immunotherapy capabilities and Medigene's T cell receptor (TCR) discovery platform to discover and develop innovative TCR immunotherapies against targets

Little has been known to date about how the immune system's natural killer (NK) cells detect which cells have been infected with SARS-CoV-2.

Press Release: BioNTech and Medigene Announce Global Collaboration to Advance T Cell Receptor Immunotherapies Against Cancer -- Collaboration leverages BioNTech's multi-platform immunotherapy

Results from an international, randomized, double-blind, placebo-controlled, phase 3 clinical trial indicate that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy prolongs the survival of men with metastatic, hormone-sensitive prostate cancer, a disease that is fatal in most cases.

T-cell responses directed against the receptor-binding domain of the SARS-CoV-2 spike protein were associated with protection from SARS-CoV-2 infection in vaccinated individuals with or without cancer, with lower T-cell responses observed in patients with blood cancers.

Researchers designed an electrochemiluminescence-based serology test with remarkable sensitivity to precisely quantify the amounts of anti-RBD antibodies in individuals infected with SARS-CoV-2.

A new study aimed to clarify whether extensive RBD mutations could affect the magnitude and immunodominance hierarchy of the host antibody response.